CIGB 300

Drug Profile

CIGB 300

Alternative Names: CIGB-300; IGBC-300; P15-Tat

Latest Information Update: 26 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for Genetic Engineering and Biotechnology
  • Developer Center for Genetic Engineering and Biotechnology; Elea; Heber Biotec
  • Class Antineoplastics; Apoptosis regulatory proteins; Peptides
  • Mechanism of Action Apoptosis stimulants; Casein kinase II inhibitors; Nucleophosmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer

Highest Development Phases

  • Phase II/III Condylomata acuminata
  • Phase II Cervical cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 01 Jan 2016 Elea completes phase II clinical trials in Cervical cancer in Argentina (Intralesional)
  • 23 Jun 2015 CIGB 300 is still in phase II trials for Cervical cancer in Argentina
  • 23 Jun 2015 Clinical development for Condylomata acuminata is ongoing in Argentina
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top